Table 4.

Multivariable analysis of endocrine dysfunction

Outcome	Covariate	Odds Ratio (95% CI) or Parameter Estimate (95% CI)	P
Hypothyroidism	PRT vs XRT	0.13 (0.04–0.41)	<.001
	CSI dose	1.75 (1.04–2.94)	.036
Growth hormone deficiency	PRT vs XRT	0.81 (0.26–2.59)	.728
	Male vs female	3.80 (1.29–11.17)	.015
	Classic histology vs others	7.07 (1.66–30.19)	.008
	Age at diagnosis	0.83 (0.71–0.97)	.018
Sex hormone deficiency	PRT vs XRT	0.06 (0.01–0.55)	.013
	Male vs female	0.31 (0.06–1.63)	.167
Endocrine replacement therapy	PRT vs XRT	0.30 (0.09–0.99)	.047
	Male vs female	2.82 (0.94–8.42)	.064
	Classic histology vs others	4.42 (1.14–17.18)	.032
	Age at diagnosis	0.90 (0.78–1.04)	.164
	CSI dose	1.30 (0.92–1.84)	.134
Height SDSa	PRT vs XRT	0.89 (0.24–1.54)	.008
	Residual disease after surgery <1.5 cm2 vs none	−0.77 (−1.81–0.28)	.153

Seventy-seven observations were used in the model. Backward variable selection method with an alpha level of 0.2 was used for all models. Models were stratified by date of diagnosis. The following variables were removed from the model when not listed: age, date of diagnosis, gender, histology, location of RT boost, CSI dose, and residual disease after surgery.

^aFor analysis of height SDS, 59 observations were used; values are parameter estimate (95% CI).